Pemphigus vulgaris: The role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production

Clinical Immunology

Volumn 100, Issue 2, 2001, Pages 172-180

  Bhol, Kailash C ^a   Desai, Alpesh ^a   Kumari, Suman ^a   Colon, Jose E ^a   Ahmed, A R ^a  

^a NEW ENGLAND BAPTIST HOSPITAL   (United States)

Author keywords

Interleukin 1 (IL 1); Interleukin 1 receptor antagonist; Intravenous immunoglobulin (IVIG); Mechanism of action; Pemphigus vulgaris

Indexed keywords

IMMUNOGLOBULIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; INFUSION; MALE; MONONUCLEAR CELL; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034904154     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.2001.5061     Document Type: Article

References (43)

1. Pemphigus: Current concept
2. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris a disease of cell adhesion
3. Death in pemphigus
4. Events leading to death of patients with pemphigus and bullous pemphigoid
5. Cyclophosphamide in the treatment of pemphigus and bullous pemphigoid
6. Immunosuppressive agents for use in dermatology
7. Use of cyclophosphamide in azathioprine failures in pemphigus
8. Immune diseases many roles for interleukin 1
9. Biology of interleukin 1
10. Effects of immune complexes on production by human monocytes of interleukin 1 or interleukin 1 inhibitor
11. Blocking IL-1: Interleukin-1 receptor antagonist in vivo and in vitro
12. Pemphigus and pemphigoid epidermocytes interfere with interleukin cascade reactions
13. Cytokines in the sera of patients with pemphigus vulgaris: Interleukin-6 and tumor necrosis factor alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity
14. Presence of interleukin-10 in the serum and blister fluid of patients with pemphigus vulgaris and pemphigoid
15. In vitro and in vivo expression of interelukin-1a and tumor necrosis factor-a mRNA in pemphigus vulgaris: Interleukin-1a and tumor necrosis factor-a are involved in acantholysis
16. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood
17. The treatment of Kawasaki syndrome with intravenous gammaglobulin
18. A controlled trial of high does intravenous immune globulin infusions as treatment for dermatomyositis
19. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris
20. Role of intravenous immunoglobulin inn the treatment of bullous pemphigoid: Analysis of current data
21. Linear IgA bullous dermatosis in a patient with chronic renal failure: Response to IVIG therapy
22. Linear IgA bullous disease limited to the eye: A diagnostic dilemma. Response to intravenous immunoglobulin therapy
23. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid. A preliminary study
24. In vitro C3 mRNA expression in pemphigus vulgaris complement activation is increased by IL-1 alpha and TNF-alpha
25. Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: Relationship with disease intensity
26. Serum levels of TNF-alpha and IL-6 in ocular cicatricial pemphigoid
27. Production of IL-1 receptor antagonist and IL-1 B by peripheral blood mononuclear cells is differentially regulated
28. Manipulating the immune system with immune globulin
29. Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/idiotypic network
30. Mechanisms of action of intravenous immune globulin in immune-mediated diseases
31. Cytokine induction in human mononuclear cells stimulated by IgG-coated culture surfaces and by IgG for infusion
32. Human intravenous immunoglobulin modulates monokine production in vitro
33. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled IgG
34. IgG for intravenous use, autologous serum and plasma induce comparable interleukin-1 receptor antagonist liberation from human mononuclear cells: An in vitro phenomenon depending upon plastic adherence
35. Intravenous immune globulin affects cytokine production in T-lymphocytes and monocytes/macrophages
36. Intravenous immunoglobulin induces interferon-Y and interleukin-6 in vivo
37. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo
38. Administration of intravenous immunoglobulin (IVIG) in vivo down-regulatory effects on the IL-1 system
39. Selective induction of interelukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin)
40. IgG induction of IL-1 receptor antagonist production by human monocytes
41. Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: Effects on disease activity and serum cytokines
42. Effects of immunoglobulin and gamma-interferon on production of tumor necrosis factor-alpha and interleukin-1beta by peripheral blood monocytes in the acute phase of Kawasaki disease
43. Production of IL-1 beta, IL-1 receptor antagonist and IL-10 by mononuclear cells from patients with SLE